ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016
MicroRNA-144 mediates metabolic shift in ovarian cancer cells by directly targeting Glut1.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Deregulated Metabolic Pathways in Ovarian Cancer: Cause and Consequence.Metabolites · 2023Review
- HIFZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2021Article
- Metabolic reprogramming in epithelial ovarian cancer.American journal of translational research · 2021Review
- microRNA-144 inhibits cell proliferation and invasion by directly targeting TIGAR in esophageal carcinoma.Oncology letters · 2020Article
- MicroRNA-144: A novel biological marker and potential therapeutic target in human solid cancers.Journal of Cancer · 2020Review
- Therapeutic potential of microRNAs in the regulation of cancer energy metabolism.Annals of translational medicine · 2019Article
- MiR-505 suppressed the growth of hepatocellular carcinoma cells via targeting IGF-1R.Bioscience reports · 2019Article
- miR-144 Potentially Suppresses Proliferation and Migration of Ovarian Cancer Cells by Targeting RUNX1.Medical science monitor basic research · 2018Article
- The Glycolytic Switch in Tumors: How Many Players Are Involved?Journal of Cancer · 2017Review
- MiR-144-3p inhibits cell proliferation and induces apoptosis in multiple myeloma by targeting c-Met.American journal of translational research · 2017Article
- Reprogramming of glucose metabolism in hepatocellular carcinoma: Progress and prospects.World journal of gastroenterology · 2016Review
- CD147 silencing inhibits tumor growth by suppressing glucose transport in melanoma.Oncotarget · 2016Article
- miRNA-451 inhibits glioma cell proliferation and invasion by downregulating glucose transporter 1.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Dichloroacetate and metformin synergistically suppress the growth of ovarian cancer cells.Oncotarget · 2016Article
- Review
- MiR-144 inhibits cell proliferation of renal cell carcinoma by targeting MTOR.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2016Article
Corrections and comments
- Retraction · 2017-04-20Compromised Peer Review · Investigation by Journal/Publisher · · Journal published by SAGE starting in 2017
- Retracted
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Warburg effect is characterized by an increased utilization of glucose via glycolysis in cancer cells, even when enough oxygen is present to properly respire. Recent studies demonstrate that deregulation of microRNAs contributes to the Warburg effect. In the present study, we show that miR-144 is downregulated while glucose transporter 1 (Glut1) is upregulated in ovarian cancers. In vitro studies further showed that miR-144 inhibits Glut1 expression through targeting its 3'-untranslated region. As a result, cells overexpressing miR-144 exhibited a metabolic shift, including enhanced glucose uptake and lactate production. The altered glucose metabolism induced by miR-144 also leads to a rapid growth of ovarian cancer cells. Taken together, our results indicate that miR-144 may serve as a molecular switch to regulate glycolysis in ovarian cancer by targeting the expression of Glut1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.